“We have the capacity to produce over 10M COVID-19 tests per week globally”
Bio Spectrum|October 2020
Thermo Fisher Scientific, the world leader in serving science, is continuously working to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments.
Dr Manbeena Chawla
“We have the capacity to produce over 10M COVID-19 tests per week globally”

The company is now supporting over 200 projects globally. The company is also supporting multiple vaccine programmes globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months. In addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need during this crisis. Amit Chopra, Managing Director, India and Middle East, Thermo Fisher Scientific, Mumbai recently spoke to BioSpectrum about the company’s initiatives to counter COVID-19, particularly in India. Edited excerpts;

How is Thermo Fisher Scientific expanding its diagnostic capacity to fight the global pandemic?

At Thermo Fisher Scientific, our mission is to enable our customers to make the world healthier, cleaner, and safer. Globally, we saw a significant increase in the spread of the virus and our customers were getting inundated. As reliable partners, our primary objective was to scale our offerings to enable them to better navigate through this pandemic. We have been actively involved in understanding the structure of the virus, developing new diagnostic tests, providing personal protective equipment, reagents, and other laboratory essential instruments, to providing tools for vaccine research and development, clinical trials and even manufacturing some of the therapeutics. TaqPath COVID-19 Combo Kits were one of the first tests to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and are being extensively used across the world.

この記事は Bio Spectrum の October 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は Bio Spectrum の October 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

BIO SPECTRUMのその他の記事すべて表示
Early Diabetic Retinopathy Detection Remains a Challenge
Bio Spectrum

Early Diabetic Retinopathy Detection Remains a Challenge

The Vitreo Retinal Society of India (VRSI) and the Research Society for the Study of Diabetes in India (RSSDI) have formulated a first-of-its kind diabetic retinopathy (DR) screening guideline to help physicians and diabetologists in India educate their patients about DR.

time-read
2 分  |
BioSpectrum India Nov 2024
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
Bio Spectrum

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum India Nov 2024
Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology
Bio Spectrum

Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology

Qiagen N.V. has announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics.

time-read
1 min  |
BioSpectrum India Nov 2024
Thermo Fisher introduces iCAP MX Series ICP-MS to simplify trace elemental analysis
Bio Spectrum

Thermo Fisher introduces iCAP MX Series ICP-MS to simplify trace elemental analysis

Thermo Fisher Scientific Inc. has launched the Thermo Scientific iCAP MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS).

time-read
1 min  |
BioSpectrum India Nov 2024
Singleron, Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Bio Spectrum

Singleron, Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum India Nov 2024
IIT Madras identifies enhanced drug delivery method for eye treatments
Bio Spectrum

IIT Madras identifies enhanced drug delivery method for eye treatments

Researchers at the Indian Institute of Technology Madras (IIT-M) have demonstrated how drugs injected in the human eye can be better delivered to the target region through ‘convection caused by mild laser heating’.

time-read
1 min  |
BioSpectrum India Nov 2024
IIT Madras develops indigenous POCUS scanner for sports injury diagnosis
Bio Spectrum

IIT Madras develops indigenous POCUS scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-Care-Ultrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum India Nov 2024
Practo strengthens Board with appointment of TVG Krishnamurthy and Dr Alexander Kuruvilla
Bio Spectrum

Practo strengthens Board with appointment of TVG Krishnamurthy and Dr Alexander Kuruvilla

Practo has appointed two new directors to its board: TVG Krishnamurthy and Dr Alexander Kuruvilla.

time-read
1 min  |
BioSpectrum India Nov 2024
Dr R N Gupta steps in as National President of Indian Pharmaceutical Association
Bio Spectrum

Dr R N Gupta steps in as National President of Indian Pharmaceutical Association

Dr R N Gupta has been elected as the National President of the Indian Pharmaceutical Association (IPA), the oldest and largest association of pharmaceutical professionals in the country, for the term 2024 - 2026 (October 1, 2024 - September 30, 2026).

time-read
1 min  |
BioSpectrum India Nov 2024
QR678 brings medtech leader Sridhar Ranganathan to advisory board
Bio Spectrum

QR678 brings medtech leader Sridhar Ranganathan to advisory board

QR678, a pioneering company dedicated to revolutionising hair and skin science through groundbreaking research and innovative solutions, has announced the appointment of Sridhar Ranganathan to its Board of Advisors.

time-read
1 min  |
BioSpectrum India Nov 2024